Tefferi A - Search Results

1

Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.

Pardanani A, Tefferi A, Masszi T, Mishchenko E, Drummond M, Jourdan E, Vannucchi A, Jurgutis M, Ribrag V, Rambaldi A, Koh LP, Rose S, Zhang J, Harrison C. Pardanani A, et al. Among authors: tefferi a. Br J Haematol. 2021 Oct;195(2):244-248. doi: 10.1111/bjh.17727. Epub 2021 Jul 30. Br J Haematol. 2021. PMID: 34331348 Free PMC article. Clinical Trial.

2

2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia.

Tefferi A, Silverstein MN, Li CY. Tefferi A, et al. Br J Haematol. 1997 Nov;99(2):352-7. doi: 10.1046/j.1365-2141.1997.3843198.x. Br J Haematol. 1997. PMID: 9375753 Free article.

3

Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia.

Elliott MA, Chen MG, Silverstein MN, Tefferi A. Elliott MA, et al. Among authors: tefferi a. Br J Haematol. 1998 Nov;103(2):505-11. doi: 10.1046/j.1365-2141.1998.00998.x. Br J Haematol. 1998. PMID: 9827926 Free article.

4

Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia.

Yoon SY, Li CY, Mesa RA, Tefferi A. Yoon SY, et al. Among authors: tefferi a. Br J Haematol. 1999 Sep;106(3):682-8. doi: 10.1046/j.1365-2141.1999.01598.x. Br J Haematol. 1999. PMID: 10468856 Free article.

5

A long-term study of patients with chronic natural killer cell lymphocytosis.

Rabbani GR, Phyliky RL, Tefferi A. Rabbani GR, et al. Among authors: tefferi a. Br J Haematol. 1999 Sep;106(4):960-6. doi: 10.1046/j.1365-2141.1999.01624.x. Br J Haematol. 1999. PMID: 10519998 Free article.

6

Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia.

Tefferi A, Jiménez T, Gray LA, Mesa RA, Chen MG. Tefferi A, et al. Eur J Haematol. 2001 Jan;66(1):37-42. doi: 10.1034/j.1600-0609.2001.00342.x. Eur J Haematol. 2001. PMID: 11168506 Review.

7

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.

Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Tefferi A, et al. Br J Haematol. 2001 Jun;113(3):763-71. doi: 10.1046/j.1365-2141.2001.02796.x. Br J Haematol. 2001. PMID: 11380468 Free article.

8

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.

Mesa RA, Tefferi A, Elliott MA, Hoagland HC, Call TG, Schroeder GS, Yoon SY, Li CY, Gray LA, Margolin S, Hook CC. Mesa RA, et al. Among authors: tefferi a. Br J Haematol. 2001 Jul;114(1):111-3. doi: 10.1046/j.1365-2141.2001.02883.x. Br J Haematol. 2001. PMID: 11472354 Free article. Clinical Trial.

9

Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia.

Tefferi A, Meyer RG, Wyatt WA, Dewald GW. Tefferi A, et al. Br J Haematol. 2001 Nov;115(2):316-9. doi: 10.1046/j.1365-2141.2001.03131.x. Br J Haematol. 2001. PMID: 11703327 Free article.

10

Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease.

Baek JY, Tefferi A, Pardanani A, Li CY. Baek JY, et al. Among authors: tefferi a. Leuk Res. 2002 Jan;26(1):83-90. doi: 10.1016/s0145-2126(01)00102-3. Leuk Res. 2002. PMID: 11734306

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,187 results

Search Page

Filters